<DOC>
	<DOCNO>NCT01845727</DOCNO>
	<brief_summary>The propose study encompass two-step approach . The first aim determine safety Topical 3 % Amphotericin B Cream apply three two time per day 4 week subject un-complicated Cutaneous leishmaniasis ( CL ) whilst second focusing indication efficacy two mention regimen Topical 3 % Amphotericin B Cream For first step , 30 subject randomly assign receive direct observe treatment ( DOT ) Topical 3 % Amphotericin B Cream apply either three two time per day 4 week . Enrolment temporarily halt 30 subject ( 15 group ) enrol complete 28 day treatment course . An interim analysis safety ( Adverse Events , include local reaction lab parameter ) pharmacokinetics collect subject randomize perform data safety monitor board . If serious adverse event ( SAEs ) relate study drug identify first 30 subject end treatment course , 50 additional subject randomly allocate receive Topical 3 % Amphotericin B Cream either three two time per day 28 day Subjects follow-up visit end therapy , Day 45± 5 day , Day 63± 5 day Days 90± 14 day Day 180 , minus 14d , plus 4 week assess efficacy , measure number subject fulfil cure criterion : 100 % re-epithelialization lesion ( ) Day 90 relapse Day 180 . All subject follow Day 180 final analysis efficacy .</brief_summary>
	<brief_title>Topical 3 % Amphotericin B Cream Treatment Cutaneous Leishmaniasis Colombia</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Subject confirm infection due L. braziliensis polymerase chain reaction assay Subject lesion satisfies follow criterion : ulcerative character ulcer size equal 0.5 cm 3 cm ( Longest diameter ) locate ear , face , close mucosal membrane , joint location opinion PI difficult maintain application study drug topically . Subject 3 lesion . Duration lesion le 3 month patient history Subject able give write informed consent opinion investigator , subject capable understanding comply protocol Female positive serum pregnancy test screen breast feeding , lactate female fertile age agree take appropriate contraception treatment period Day 45 . History clinically significant medical problem treatment might interact , either negatively positively , topical treatment leishmaniasis include immunocompromising condition . Within 8 week ( 56 day ) start study treatment , receive treatment leishmaniasis medication include antimonials likely , opinion PI , modify course Leishmania infection Has diagnosis suspect diagnosis mucocutaneous leishmaniasis base physical exam . History know suspected hypersensitivity idiosyncratic reaction amphotericin Has laboratory value screen follow : Haemoglobin 10 gram , Serum creatinine normal level , alanine aminotransferase aspartate aminotransferase 3 time normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Topical treatment</keyword>
	<keyword>Colombia</keyword>
</DOC>